Ortega-Rodriguez Uriel, Portillo Susana, Ashmus Roger A, Duran Jerry A, Schocker Nathaniel S, Iniguez Eva, Montoya Alba L, Zepeda Brenda G, Olivas Janet J, Karimi Nasim H, Alonso-Padilla Julio, Izquierdo Luis, Pinazo Maria-Jesús, de Noya Belkisyolé Alarcón, Noya Oscar, Maldonado Rosa A, Torrico Faustino, Gascon Joaquim, Michael Katja, Almeida Igor C
Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, USA.
Department of Chemistry and Biochemistry, University of Texas at El Paso, El Paso, TX, USA.
Methods Mol Biol. 2019;1955:287-308. doi: 10.1007/978-1-4939-9148-8_22.
Chagas disease (ChD), caused by the protozoan parasite Trypanosoma cruzi, affects millions of people worldwide. Chemotherapy is restricted to two drugs, which are partially effective and may cause severe side effects, leading to cessation of treatment in a significant number of patients. Currently, there are no biomarkers to assess therapeutic efficacy of these drugs in the chronic stage. Moreover, no preventive or therapeutic vaccines are available. In this chapter, we describe the purification of Trypanosoma cruzi trypomastigote-derived glycosylphosphatidylinositol (GPI)-anchored mucins (tGPI-mucins) for their use as antigens for the reliable primary or confirmatory diagnosis and as prognostic biomarkers for early assessment of cure following ChD chemotherapy. We also describe, as an example, the synthesis of a potential tGPI-mucin-derived α-Gal-terminating glycan and its coupling to a carrier protein for use as diagnostic and prognostic biomarker in ChD.
恰加斯病（ChD）由原生动物寄生虫克氏锥虫引起，影响着全球数百万人。化疗仅限于两种药物，它们部分有效且可能会引起严重的副作用，导致大量患者停止治疗。目前，尚无生物标志物可用于评估这些药物在慢性期的治疗效果。此外，也没有预防性或治疗性疫苗。在本章中，我们描述了克氏锥虫滋养体衍生的糖基磷脂酰肌醇（GPI）锚定粘蛋白（tGPI-粘蛋白）的纯化方法，这些粘蛋白用作抗原可用于可靠的初步或确诊诊断，以及作为预后生物标志物用于恰加斯病化疗后治愈情况的早期评估。我们还举例描述了一种潜在的tGPI-粘蛋白衍生的α-半乳糖末端聚糖的合成及其与载体蛋白的偶联，用作恰加斯病的诊断和预后生物标志物。
